Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis

Autoimmunity Reviews

Volumn 13, Issue 10, 2014, Pages 1020-1025

  Yan, Zheng ^b   kui, Zhang ^b   Ping, Zhu ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

Genomics research; Idiopathic pulmonary fibrosis; Signaling pathway; Systems biology

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; WNT PROTEIN;

BIOINFORMATICS; DIAGNOSTIC VALUE; FIBROSING ALVEOLITIS; GENETIC ASSOCIATION; GENOMICS; HUMAN; LUNG ALVEOLUS EPITHELIUM; MOLECULAR PATHOLOGY; NONHUMAN; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; ANIMAL; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM; LUNG; METABOLISM; PATHOLOGY;

ANIMALS; EPITHELIAL-MESENCHYMAL TRANSITION; EPITHELIUM; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; SIGNAL TRANSDUCTION;

EID: 84908126634     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.08.028     Document Type: Review

References (87)

1. Mura M., Porretta M.A., Bargagli E., Sergiacomi G., Zompatori M., Sverzellati N., et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J 07-01-2012, 40(1):101-109.
2. Gharaee-Kermani M., Gyetko M.R., Hu B., Phan S.H. New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy. Pharm Res 05-01-2007,24(5):819-841.
3. Selman M., King T.E., Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 01-16-2001,134(2):136-151.
4. Selman M., Pardo A. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. Respir Res 01-20-2002,3:3.
5. Fernandez I.E., Eickelberg O. The impact of TGF-beta on lung fibrosis: from targeting to biomarkers. Proc Am Thorac Soc 07-01-2012,9(3):111-116.
6. McMillan M., Kahn M. Investigating Wnt signaling: a chemogenomic safari. Drug Discov Today 11-01-2005,10(21):1467-1474.
7. Ou X.M., Li W.C., Liu D.S., Li Y.P., Wen F.Q., Feng Y.L., et al. VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice. Int Immunopharmacol 01-01-2009,9(1):70-79.
8. Antoniou K.M., Margaritopoulos G.A., Soufla G., Symvoulakis E., Vassalou E., Lymbouridou R., et al. Expression analysis of Akt and MAPK signaling pathways in lung tissue of patients with idiopathic pulmonary fibrosis (IPF). J Recept Signal Transduct Res 08-01-2010,30(4):262-269.
9. Hardie W.D., Hagood J.S., Dave V., Perl A.K., Whitsett J.A., Korfhagen T.R., et al. Signaling pathways in the epithelial origins of pulmonary fibrosis. Cell Cycle 07-15-2010,9(14):2769-2776.
10. Fernandez I.E., Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 08-18-2012,380(9842):680-688.
11. Noth I., Zhang Y., Ma S.F., Flores C., Barber M., Huang Y., et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 06-01-2013,1(4):309-317.
12. Kass D.J., Kaminski N. Evolving genomic approaches to idiopathic pulmonary fibrosis: moving beyond genes. Clin Transl Sci 10-01-2011,4(5):372-379.
13. Horton C.J., Mitui M., Leos N.K., Garcia C.K., Park J.Y. Long-range PCR based sequencing of the highly homologous genes, SFTPA1 and SFTPA2. Mol Cell Probes 06-01-2013,27(3-4):115-117.
14. Nance T., Smith K.S., Anaya V., Richardson R., Ho L., Pala M., et al. Transcriptome analysis reveals differential splicing events in IPF lung tissue. PLoS One 01-20-2014,9(3):e92111.
15. Lee K.S., Park S.J., Kim S.R., Min K.H., Lee K.Y., Choe Y.H., et al. Inhibition of VEGF blocks TGF-beta1 production through a PI3K/Akt signalling pathway. Eur Respir J 03-01-2008,31(3):523-531.
16. Meltzer E.B., Noble P.W. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 01-20-2008,3:8.
17. Wilson M.S., Wynn T.A. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol 03-01-2009,2(2):103-121.
18. Abe R., Donnelly S.C., Peng T., Bucala R., Metz C.N. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 06-15-2001,166(12):7556-7562.
19. Willis B.C., Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 09-01-2007,293(3):L525-L534.
20. Andersson-Sjoland A., de Alba C.G., Nihlberg K., Becerril C., Ramirez R., Pardo A., et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 01-20-2008,40(10):2129-2140.
21. Mehrad B., Burdick M.D., Zisman D.A., Keane M.P., Belperio J.A., Strieter R.M. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 02-02-2007,353(1):104-108.
22. Wu Z., Yang L., Cai L., Zhang M., Cheng X., Yang X., et al. Detection of epithelial to mesenchymal transition in airways of a bleomycin induced pulmonary fibrosis model derived from an alpha-smooth muscle actin-Cre transgenic mouse. Respir Res 01-20-2007,8:1.
23. Kim K.K., Kugler M.C., Wolters P.J., Robillard L., Galvez M.G., Brumwell A.N., et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci U S A 08-29-2006,103(35):13180-13185.
24. Kasai H., Allen J.T., Mason R.M., Kamimura T., Zhang Z. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 01-20-2005,6:56.
25. Kalluri R., Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 12-01-2003,112(12):1776-1784.
26. Vallance B.A., Gunawan M.I., Hewlett B., Bercik P., Van Kampen C., Galeazzi F., et al. TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis. Am J Physiol Gastrointest Liver Physiol 07-01-2005,289(1):G116-G128.
27. Chapman H.A. Disorders of lung matrix remodeling. J Clin Invest 01-01-2004,113(2):148-157.
28. Sime P.J., O'Reilly K.M. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol 06-01-2001,99(3):308-319.
29. Nawshad A., Lagamba D., Polad A., Hay E.D. Transforming growth factor-beta signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis. Cells Tissues Organs 01-20-2005,179(1-2):11-23.
30. Li Y., Yang J., Dai C., Wu C., Liu Y. Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis. J Clin Invest 08-01-2003,112(4):503-516.
31. Bowley E., O'Gorman D.B., Gan B.S. Beta-catenin signaling in fibroproliferative disease. J Surg Res 03-01-2007,138(1):141-150.
32. Chilosi M., Poletti V., Zamo A., Lestani M., Montagna L., Piccoli P., et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 05-01-2003,162(5):1495-1502.
33. Henderson W.J., Chi E.Y., Ye X., Nguyen C., Tien Y.T., Zhou B., et al. Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci U S A 08-10-2010,107(32):14309-14314.
34. Caraci F., Gili E., Calafiore M., Failla M., La Rosa C., Crimi N., et al. TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacol Res 04-01-2008,57(4):274-282.
35. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 12-01-2003,31(Pt. 6):1171-1177.
36. Schlaepfer D.D., Hauck C.R., Sieg D.J. Signaling through focal adhesion kinase. Prog Biophys Mol Biol 01-19-1999,71(3-4):435-478.
37. Zhao X., Guan J.L. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev 07-18-2011,63(8):610-615.
38. Sieg D.J., Hauck C.R., Ilic D., Klingbeil C.K., Schaefer E., Damsky C.H., et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 05-01-2000,2(5):249-256.
39. Lagares D., Busnadiego O., Garcia-Fernandez R.A., Kapoor M., Liu S., Carter D.E., et al. Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation. Arthritis Rheum 05-01-2012,64(5):1653-1664.
40. Parsons J.T. Focal adhesion kinase: the first ten years. J Cell Sci 04-15-2003,116(Pt. 8):1409-1416.
41. Hayasaka H., Simon K., Hershey E.D., Masumoto K.H., Parsons J.T. FRNK, the autonomously expressed C-terminal region of focal adhesion kinase, is uniquely regulated in vascular smooth muscle: analysis of expression in transgenic mice. J Cell Biochem 08-15-2005,95(6):1248-1263.
42. Ding Q., Cai G.Q., Hu M., Yang Y., Zheng A., Tang Q., et al. FAK-related nonkinase is a multifunctional negative regulator of pulmonary fibrosis. Am J Pathol 05-01-2013,182(5):1572-1584.
43. Silva S.R., Bowen K.A., Rychahou P.G., Jackson L.N., Weiss H.L., Lee E.Y., et al. VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis. Int J Cancer 03-01-2011,128(5):1045-1056.
44. Tang J., Wang J., Kong X., Yang J., Guo L., Zheng F., et al. Vascular endothelial growth factor promotes cardiac stem cell migration via the PI3K/Akt pathway. Exp Cell Res 12-10-2009,315(20):3521-3531.
45. Kobayashi T., Liu X., Wen F.Q., Fang Q., Abe S., Wang X.Q., et al. Smad3 mediates TGF-beta1 induction of VEGF production in lung fibroblasts. Biochem Biophys Res Commun 02-11-2005,327(2):393-398.
46. Clifford R.L., Deacon K., Knox A.J. Novel regulation of vascular endothelial growth factor-A (VEGF-A) by transforming growth factor (beta)1: requirement for Smads, (beta)-CATENIN, AND GSK3(beta). J Biol Chem 12-19-2008,283(51):35337-35353.
47. Antoniu S.A., Kolb M.R. Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis. IDrugs 05-01-2010,13(5):332-345.
48. Woodcock H.V., Molyneaux P.L., Maher T.M. Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib. Drug Des Devel Ther 01-20-2013,7:503-510.
49. Wan Y.Y., Tian G.Y., Guo H.S., Kang Y.M., Yao Z.H., Li X.L., et al. Endostatin, an angiogenesis inhibitor, ameliorates bleomycin-induced pulmonary fibrosis in rats. Respir Res 01-20-2013,14(1):56.
50. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 05-31-2002,296(5573):1655-1657.
51. Tang J.M., He Q.Y., Guo R.X., Chang X.J. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer-J Iaslc 02-01-2006,51(2):181-191.
52. Xia H., Khalil W., Kahm J., Jessurun J., Kleidon J., Henke C.A. Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis. Am J Pathol 06-01-2010,176(6):2626-2637.
53. Nho R.S., Xia H., Diebold D., Kahm J., Kleidon J., White E., et al. PTEN regulates fibroblast elimination during collagen matrix contraction. J Biol Chem 11-03-2006,281(44):33291-33301.
54. Nho R.S., Hergert P., Kahm J., Jessurun J., Henke C. Pathological alteration of FoxO3a activity promotes idiopathic pulmonary fibrosis fibroblast proliferation on type i collagen matrix. Am J Pathol 11-01-2011,179(5):2420-2430.
55. Nho R.S., Peterson M., Hergert P., Henke C.A. FoxO3a (Forkhead Box O3a) deficiency protects Idiopathic Pulmonary Fibrosis (IPF) fibroblasts from type I polymerized collagen matrix-induced apoptosis via caveolin-1 (cav-1) and Fas. PLoS One 01-20-2013,8(4):e61017.
56. Ruan G.X., Kazlauskas A. VEGF-A engages at least three tyrosine kinases to activate PI3K/Akt. Cell Cycle 06-01-2012,11(11):2047-2048.
57. Song G., Ouyang G., Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 01-01-2005,9(1):59-71.
58. Lee M.K., Pardoux C., Hall M.C., Lee P.S., Warburton D., Qing J., et al. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. Embo J 09-05-2007,26(17):3957-3967.
59. Zhou B.P., Deng J., Xia W., Xu J., Li Y.M., Gunduz M., et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 10-01-2004,6(10):931-940.
60. Bachelder R.E., Yoon S.O., Franci C., de Herreros A.G., Mercurio A.M. Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J Cell Biol 01-03-2005,168(1):29-33.
61. Redente E.F., Keith R.C., Janssen W., Henson P.M., Ortiz L.A., Downey G.P., et al. Tumor necrosis factor-alpha accelerates the resolution of established pulmonary fibrosis in mice by targeting profibrotic lung macrophages. Am J Respir Cell Mol Biol 04-01-2014,50(4):825-837.
62. Shi K., Jiang J., Ma T., Xie J., Duan L., Chen R., et al. Pathogenesis pathways of idiopathic pulmonary fibrosis in bleomycin-induced lung injury model in mice. Respir Physiol Neurobiol 01-01-2014,190:113-117.
63. Nho R.S., Hergert P. IPF fibroblasts are desensitized to type I collagen matrix-induced cell death by suppressing low autophagy via aberrant Akt/mTOR kinases. PLoS One 01-20-2014,9(4):e94616.
64. Wrzodek C., Eichner J., Buchel F., Zell A. InCroMAP: integrated analysis of cross-platform microarray and pathway data. Bioinformatics 02-15-2013,29(4):506-508.
65. Eichner J., Rosenbaum L., Wrzodek C., Haring H.U., Zell A., Lehmann R. Integrated enrichment analysis and pathway-centered visualization of metabolomics, proteomics, transcriptomics, and genomics data by using the InCroMAP software. J Chromatogr B Analyt Technol Biomed Life Sci 2014, 966:77-82.
66. Ballard D.H., Aporntewan C., Lee J.Y., Lee J.S., Wu Z., Zhao H. A pathway analysis applied to Genetic Analysis Workshop 16 genome-wide rheumatoid arthritis data. BMC Proc 01-20-2009,3(Suppl. 7):S91.
67. Priori R., Scrivo R., Brandt J., Valerio M., Casadei L., Valesini G., et al. Metabolomics in rheumatic diseases: the potential of an emerging methodology for improved patient diagnosis, prognosis, and treatment efficacy. Autoimmun Rev 08-01-2013,12(10):1022-1030.
68. Sui W., Hou X., Che W., Yang M., Dai Y. The applied basic research of systemic lupus erythematosus based on the biological omics. Genes Immun 04-01-2013,14(3):133-146.
69. Rosas I.O., Richards T.J., Konishi K., Zhang Y., Gibson K., Lokshin A.E., et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 04-29-2008,5(4):e93.
70. Selman M., Carrillo G., Estrada A., Mejia M., Becerril C., Cisneros J., et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One 01-20-2007,2(5):e482.
71. Yang I.V., Luna L.G., Cotter J., Talbert J., Leach S.M., Kidd R., et al. The peripheral blood transcriptome identifies the presence and extent of disease in idiopathic pulmonary fibrosis. PLoS One 01-20-2012,7(6):e37708.
72. Maher T.M. PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery. Eur Respir Rev 06-01-2013,22(128):148-152.
73. Seibold M.A., Wise A.L., Speer M.C., Steele M.P., Brown K.K., Loyd J.E., et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 04-21-2011,364(16):1503-1512.
74. Zhu L., Wang L., Luo X., Zhang Y., Ding Q., Jiang X., et al. Tollip, an intracellular trafficking protein, is a novel modulator of the transforming growth factor-beta signaling pathway. J Biol Chem 11-16-2012,287(47):39653-39663.
75. Samara K.D., Antoniou K.M., Karagiannis K., Margaritopoulos G., Lasithiotaki I., Koutala E., et al. Expression profiles of Toll-like receptors in non-small cell lung cancer and idiopathic pulmonary fibrosis. Int J Oncol 05-01-2012,40(5):1397-1404.
76. He Z., Zhu Y., Jiang H. Inhibiting toll-like receptor 4 signaling ameliorates pulmonary fibrosis during acute lung injury induced by lipopolysaccharide: an experimental study 01-20-2009,10:126.
77. Peljto A.L., Zhang Y., Fingerlin T.E., Ma S.F., Garcia J.G., Richards T.J., et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 06-05-2013,309(21):2232-2239.
78. Zhang Y., Noth I., Garcia J.G., Kaminski N. A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N Engl J Med 04-21-2011,364(16):1576-1577.
79. Borie R., Crestani B., Dieude P., Nunes H., Allanore Y., Kannengiesser C., et al. The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PLoS One 01-20-2013,8(8):e70621.
80. Litwack E.D., Babey R., Buser R., Gesemann M., O'Leary D.D. Identification and characterization of two novel brain-derived immunoglobulin superfamily members with a unique structural organization. Mol Cell Neurosci 02-01-2004,25(2):263-274.
81. Richards T.J., Kaminski N., Baribaud F., Flavin S., Brodmerkel C., Horowitz D., et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 01-01-2012,185(1):67-76.
82. Melas I.N., Mitsos A., Messinis D.E., Weiss T.S., Alexopoulos L.G. Combined logical and data-driven models for linking signalling pathways to cellular response. BMC Syst Biol 01-20-2011,5:107.
83. Eleftherohorinou H., Wright V., Hoggart C., Hartikainen A.L., Jarvelin M.R., Balding D., et al. Pathway analysis of GWAS provides new insights into genetic susceptibility to 3 inflammatory diseases. PLoS One 01-20-2009,4(11):e8068.
84. Jarvis J.N., Frank M.B. Functional genomics and rheumatoid arthritis: where have we been and where should we go?. Genome Med 01-20-2010,2(7):44.
85. Mitsos A., Melas I.N., Morris M.K., Saez-Rodriguez J., Lauffenburger D.A., Alexopoulos L.G. Non Linear Programming (NLP) formulation for quantitative modeling of protein signal transduction pathways. PLoS One 01-20-2012,7(11):e50085.
86. Bader G.D., Cary M.P., Sander C. Pathguide: a pathway resource list. Nucleic Acids Res 01-01-2006,34(Database issue):D504-D506.
87. Buchel F., Mittag F., Wrzodek C., Zell A., Gasser T., Sharma M. Integrative pathway-based approach for genome-wide association studies: identification of new pathways for rheumatoid arthritis and type 1 diabetes. PLoS One 01-20-2013,8(10):e78577.